Last edition
News about "Alembic Pharma Manufacturing"
Alembic Pharma Gets USFDA Nod for Ophthalmic Suspension With CGT Manufacturing Advantage
The product has been granted Competitive Generic Therapy (CGT) designation, making Alembic eligible for 180 days of market exclusivity in the USA once the product is launched. This exclusivity period provides a significant commercial advantage by limiting competition during initial marketing.
Alembic Pharma Manufacturing | 12/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members